Szerenyi D, Jarvas G, Guttman A
Molecules. 2025; 30(5).
PMID: 40076201
PMC: 11901967.
DOI: 10.3390/molecules30050976.
Bergmann L, Afflerbach A, Yuan T, Pantel K, Smit D
Semin Immunopathol. 2025; 47(1):14.
PMID: 39893314
PMC: 11787191.
DOI: 10.1007/s00281-025-01042-z.
Jiang H
Cancer Manag Res. 2024; 16:1031-1042.
PMID: 39165347
PMC: 11335005.
DOI: 10.2147/CMAR.S479338.
Roumeliotou A, Strati A, Chamchougia F, Xagara A, Tserpeli V, Smilkou S
Cells. 2024; 13(9.
PMID: 38727318
PMC: 11083423.
DOI: 10.3390/cells13090782.
Nguyen T, Huang P, Chu P, Hsieh C, Wu M
Cancers (Basel). 2023; 15(22).
PMID: 38001632
PMC: 10670359.
DOI: 10.3390/cancers15225372.
Assessment of Different Circulating Tumor Cell Platforms for Uveal Melanoma: Potential Impact for Future Routine Clinical Practice.
Martel A, Mograbi B, Romeo B, Gastaud L, Lalvee S, Zahaf K
Int J Mol Sci. 2023; 24(13).
PMID: 37446253
PMC: 10342234.
DOI: 10.3390/ijms241311075.
Phenotypic Characterization of Circulating Tumor Cells Isolated from Non-Small and Small Cell Lung Cancer Patients.
Roumeliotou A, Pantazaka E, Xagara A, Dimitrakopoulos F, Koutras A, Christopoulou A
Cancers (Basel). 2023; 15(1).
PMID: 36612166
PMC: 9818148.
DOI: 10.3390/cancers15010171.
Comparison of sample preparation methods for rare cell isolation in microfluidic devices.
Varillas J, Chen K, Dopico P, Zhang J, George T, Fan Z
Can J Chem. 2022; 100(7):512-519.
PMID: 36338875
PMC: 9635407.
DOI: 10.1139/cjc-2021-0229.
Detection and Characterization of Circulating Tumor Cells Using Imaging Flow Cytometry-A Perspective Study.
Muchlinska A, Smentoch J, Zaczek A, Bednarz-Knoll N
Cancers (Basel). 2022; 14(17).
PMID: 36077716
PMC: 9454939.
DOI: 10.3390/cancers14174178.
Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation.
Woo H, Kim S, Kang H, Lee S, Lee S, Kim J
Theranostics. 2022; 12(8):3676-3689.
PMID: 35664056
PMC: 9131262.
DOI: 10.7150/thno.72511.
Detyrosinated α-Tubulin, Vimentin and PD-L1 in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer (NSCLC) Patients.
Katsarou S, Messaritakis I, Voumvouraki A, Kakavogiannis S, Kotsakis A, Alkahtani S
J Pers Med. 2022; 12(2).
PMID: 35207643
PMC: 8875112.
DOI: 10.3390/jpm12020154.
Predictive Value of Circulating Tumor Cells Detected by ISET in Patients with Non-Metastatic Prostate Cancer Undergoing Radical Prostatectomy.
Garrido Castillo L, Mejean A, Vielh P, Anract J, Decina A, Nalpas B
Life (Basel). 2022; 12(2).
PMID: 35207452
PMC: 8877346.
DOI: 10.3390/life12020165.
Strategies for Isolating and Propagating Circulating Tumor Cells in Men with Metastatic Prostate Cancer.
Theil G, Bialek J, Weiss C, Lindner F, Fornara P
Diagnostics (Basel). 2022; 12(2).
PMID: 35204587
PMC: 8870963.
DOI: 10.3390/diagnostics12020497.
Breast cancer circulating tumor cells with mesenchymal features-an unreachable target?.
Topa J, Gresner P, Zaczek A, Markiewicz A
Cell Mol Life Sci. 2022; 79(2):81.
PMID: 35048186
PMC: 8770434.
DOI: 10.1007/s00018-021-04064-6.
Current methodologies to detect circulating tumor cells: a focus on ovarian cancer.
Lemma S, Perrone A, De Iaco P, Gasparre G, Kurelac I
Am J Cancer Res. 2021; 11(9):4111-4126.
PMID: 34659879
PMC: 8493391.
Comparison of hormonal receptor expression and HER2 status between circulating tumor cells and breast cancer metastases.
Sanches S, Braun A, Calsavara V, Barbosa P, Chinen L
Clinics (Sao Paulo). 2021; 76:e2971.
PMID: 34644733
PMC: 8478133.
DOI: 10.6061/clinics/2021/e2971.
Circulating Tumor Cells (CTCs): A Unique Model of Cancer Metastases and Non-invasive Biomarkers of Therapeutic Response.
Liu J, Lian J, Chen Y, Zhao X, Du C, Xu Y
Front Genet. 2021; 12:734595.
PMID: 34512735
PMC: 8424190.
DOI: 10.3389/fgene.2021.734595.
Evaluation of Monocarboxylate Transporter 4 ( Expression and Its Prognostic Significance in Circulating Tumor Cells From Patients With Early Stage Non-Small-Cell Lung Cancer.
Markou A, Tzanikou E, Kallergi G, Pantazaka E, Georgoulias V, Kotsakis A
Front Cell Dev Biol. 2021; 9:641978.
PMID: 33968927
PMC: 8100022.
DOI: 10.3389/fcell.2021.641978.
Promising Role of Circulating Tumor Cells in the Management of SCLC.
De Luca A, Gallo M, Esposito C, Morabito A, Normanno N
Cancers (Basel). 2021; 13(9).
PMID: 33922300
PMC: 8122820.
DOI: 10.3390/cancers13092029.
A Review of Circulating Tumour Cell Enrichment Technologies.
Rushton A, Nteliopoulos G, Shaw J, Coombes R
Cancers (Basel). 2021; 13(5).
PMID: 33652649
PMC: 7956528.
DOI: 10.3390/cancers13050970.